Back to search

Article

Efficacy of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR-mutations

2022-05-05

Abstract excerpt

<h4>Objective: </h4> Immune checkpoint inhibitors (ICIs) have been validated in epidermal growth factor receptor (EGFR) wild-type advanced non-small cell lung cancer (NSCLC) patients. However, there exists no evidence regarding EGFR-mutated NSCLC patients, especially in EGFR-TKI (tyrosine kinase inhibitor) treatment failure. To address this, we collected clinical information from two cohorts and conducted a time s...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9370755a-e22a-52ff-92ea-eedf85186b3f
DOI
10.21203/rs.3.rs-1618605/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR-mutationsDOI 10.21203/rs.3.rs-1618605/v1
Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations.Semantic proximity
Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.Semantic proximity
Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.Semantic proximity
Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in advanced non-small cell lung cancer: A systematic review of randomized controlled trialsSemantic proximity
Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis.Semantic proximity
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.Semantic proximity
Immunotherapy for TKI-resistant, EGFR L858R-mutated non-small cell lung cancer: a systematic review and meta-analysis of randomized and single-arm studies.Semantic proximity
Comparative Safety of Immune Checkpoint Inhibitors and Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-AnalysisSemantic proximity
Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.Semantic proximity
Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.Semantic proximity
The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis.Semantic proximity
Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.Semantic proximity
Select a neighboring publication to make it the new centre.